Key result
Ginsenoside Rg1 decreased levels of glucose, insulin, triglycerides, and total cholesterol, inhibited inflammatory cytokines, and improved liver lipid metabolism in NAFLD model rats.
Why the study?
The study was conducted to establish the molecular mechanism of ginsenoside Rg1 in nonalcoholic fatty liver disease (NAFLD).
Does ginsenoside Rg1 improve lipid metabolism and alleviate liver injury in a NAFLD rat model?
Does ginsenoside Rg1 improve lipid metabolism and alleviate liver injury in a NAFLD rat model?
Ginsenoside Rg1 regulates lipid metabolism and alleviates liver injury and inflammation in a rat model of NAFLD.
Hypothesis-generating for ginsenoside Rg1 in rat NAFLD; should not change practice without human trials.
To establish the molecular mechanism of ginsenoside Rg1 in nonalcoholic fatty liver disease (NAFLD), Sprague Dawley (SD) rats (180-220 g) were randomly divided into a control group, model group, ginsenoside Rg1 low-dose group (30 mg/(kg day)), high-dose (60 mg/(kg day)) group, and simvastatin group (1 mg/(kg day)), with 10 SD rats in each group. The control group was given a normal diet. The model group rats were given high-sugar and high-fat diets for 14 weeks. After the model of NAFLD was established successfully, ginsenoside Rg1 was administered orally for 4 or 8 weeks. The results showed that ginsenoside Rg1 decreased the levels of glucose (GLU), insulin (INS), triglyceride (TG), and total cholesterol (TC) and improved liver function. Meanwhile, ginsenoside Rg1 inhibited the secretion of interleukin-1 (IL-1), IL-6, IL-8, IL-18, and tumor necrosis factor-α (TNF-α) and improved hepatocyte morphology and lipid accumulation in the liver. Furthermore, ginsenoside Rg1 promoted the expression of peroxisome proliferator-activated receptor-α (PPAR-α), carnitine palmitoyl transferase 1α (CPT1A), carnitine palmitoyl transferase 2 (CPT2), and cholesterol 7α-hydroxylase (CYP-7A) and inhibited the expression of sterol regulatory element binding proteins-1C (SREBP-1C). In conclusion, ginsenoside Rg1 can inhibit inflammatory reaction, regulate lipid metabolism, and alleviate liver injury in NAFLD model rats.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2020) studied Nonalcoholic fatty liver disease (NAFLD) (n=50). Ginsenoside Rg1 vs. Model group (high-sugar and high-fat diet) and simvastatin group was evaluated on Levels of glucose, insulin, triglycerides, total cholesterol, and inflammatory markers. Ginsenoside Rg1 decreased levels of glucose, insulin, triglycerides, and total cholesterol, inhibited inflammatory cytokines, and improved liver lipid metabolism in NAFLD model rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: